These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32489004)

  • 1. Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A cross-sectional study.
    Takahashi K; Yamazawa R; Suzuki T; Mimura M; Uchida H
    Neuropsychopharmacol Rep; 2020 Sep; 40(3):232-238. PubMed ID: 32489004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients].
    Jalenques I; Ortega V; Legrand G; Auclair C
    Encephale; 2016 Apr; 42(2):124-9. PubMed ID: 26796558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation.
    Roberts LW; Warner TD; Nguyen KP; Geppert CM; Rogers MK; Roberts BB
    Psychopharmacology (Berl); 2003 Dec; 171(1):58-67. PubMed ID: 12756518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation.
    Day JC; Kinderman P; Bentall R
    Acta Psychiatr Scand; 1998 Jan; 97(1):93-7. PubMed ID: 9504710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia.
    Patel MX; Nikolaou V; David AS
    Psychol Med; 2003 Jan; 33(1):83-9. PubMed ID: 12537039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.
    Bick P; Knoesen N; Castle D
    Australas Psychiatry; 2007 Dec; 15(6):465-9. PubMed ID: 17999256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatrist and patient responses to suspected medication nonadherence in schizophrenia spectrum disorders.
    Hamann J; Lipp ML; Christ-Zapp S; Spellmann I; Kissling W
    Psychiatr Serv; 2014 Jul; 65(7):881-7. PubMed ID: 24686753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can psychiatrists and neurologists predict their patients' participation preferences?
    Hamann J; Mendel R; Schebitz M; Reiter S; Bühner M; Cohen R; Berthele A; Kissling W
    J Nerv Ment Dis; 2010 Apr; 198(4):309-11. PubMed ID: 20386262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.
    Correll CU; Brevig T; Brain C
    BMC Psychiatry; 2019 Nov; 19(1):362. PubMed ID: 31727015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with schizophrenia assessing psychiatrists' communication skills.
    Pestana-Santos A; Loureiro L; Santos V; Carvalho I
    Psychiatry Res; 2018 Nov; 269():13-20. PubMed ID: 30145294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychiatrists' psychotropic drug prescription preferences for themselves or their family members.
    Latas M; Stojkovic T; Ralic T; Milovanovic S; Jasovic-Gasic M
    Psychiatr Danub; 2012 Jun; 24(2):182-7. PubMed ID: 22706417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission as perceived by people with schizophrenia, family members and psychiatrists.
    Karow A; Naber D; Lambert M; Moritz S;
    Eur Psychiatry; 2012 Aug; 27(6):426-31. PubMed ID: 21571506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey.
    Nagai N; Tani H; Suzuki T; Ikai S; Gerretsen P; Mimura M; Uchida H
    Pharmacopsychiatry; 2017 Nov; 50(6):264-269. PubMed ID: 28675911
    [No Abstract]   [Full Text] [Related]  

  • 16. [PRESCRIPTION PATTERNS IN THE TREATMENT OF SCHIZOPHRENIA].
    Leiderman EA; Lorenzo L
    Vertex; 2015; 26(119):11-6. PubMed ID: 26323108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia.
    Achtyes E; Simmons A; Skabeev A; Levy N; Jiang Y; Marcy P; Weiden PJ
    BMC Psychiatry; 2018 Sep; 18(1):292. PubMed ID: 30223804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effectiveness in patients with schizophrenia as measured by the ASSESS battery - first longitudinal data.
    Ladea M; Barbu CM; Juckel G
    Psychiatr Danub; 2015 Dec; 27(4):364-70. PubMed ID: 26609648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' and psychiatrists' perceptions of clinical decisions during schizophrenia treatment.
    Hamann J; Mendel RT; Fink B; Pfeiffer H; Cohen R; Kissling W
    J Nerv Ment Dis; 2008 Apr; 196(4):329-32. PubMed ID: 18414128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatrists' Attitude and Use of Second-generation Antipsychotics for the Treatment of Schizophrenia in Taiwan.
    Chen CK; Su HH; Sun IW
    East Asian Arch Psychiatry; 2017 Sep; 27(3):91-6. PubMed ID: 28993541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.